C. Campbell

发表

Plasmablastic lymphoma: a new subcategory of human immunodeficiency virus-related non-Hodgkin's lymphoma.

R. Miller, M. Spittle, R. Brown, 1998, Clinical oncology (Royal College of Radiologists (Great Britain)).

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial

R. Gelber, S. Loi, M. Piccart, 2019, Breast Cancer Research and Treatment.

Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

S. Loi, S. Loibl, F. André, 2019, Clinical Cancer Research.

Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.

J. Robertson, R. Paridaens, I. Bradbury, 2021, European journal of cancer.

Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin's lymphoma without G-CSF support.

E. Franssen, C. Sawka, N. Berinstein, 1999, Leukemia & lymphoma.

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials

R. Gelber, J. Baselga, M. Ignatiadis, 2018, Cancer.

Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies

J. Robertson, R. Paridaens, S. Johnston, 2021, NPJ breast cancer.

E. Perez, M. Piccart, H. Gómez, 2016, Journal of the National Cancer Institute.

Abstract P1-13-02: Visceral metastases from hormone receptor positive breast cancer are as sensitive to endocrine therapy as non-visceral metastases

J. Robertson, R. Paridaens, J. Bogaerts, 2015 .

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

R. Gelber, M. Piccart, S. Lakhani, 2021, The New England journal of medicine.

Circulating Tumor DNA in HER2-Ampli ﬁ ed Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

C. Sotiriou, S. Loi, M. Piccart, 2019 .

Circulating tumor DNA in HER2 amplified breast cancer: a translational research substudy of the NeoALTTO phase 3 trial

C. Sotiriou, S. Loi, M. Piccart, 2019 .

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.

R. Gelber, A. Tutt, S. Lakhani, 2021 .

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.

Carsten Denkert, Stefan Michiels, Christos Sotiriou, 2015, JAMA oncology.

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

R. Gelber, M. Piccart, J. Baselga, 2018, Journal of the National Cancer Institute.

Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance

I. Ellis, A. Green, J. Robertson, 2020, Translational Breast Cancer Research.

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer

M. Ellis, J. Robertson, I. Bradbury, 2019, Breast Cancer.

Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.

K. Gelmon, D. Ayers, A. Tolcher, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

E. Perez, R. Gelber, J. Costantino, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer.

K. Gelmon, D. Ayers, A. Tolcher, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.

N. Thatcher, M. Lind, C. Campbell, 1989, British Journal of Cancer.

High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab

M. Piccart, L. Pusztai, J. Baselga, 2014, Clinical Cancer Research.

Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies

R. Paridaens, S. Chia, I. Bradbury, 2021, npj Breast Cancer.

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)

M. Piccart, L. Pusztai, Dar-Ren Chen, 2017, Breast Cancer Research and Treatment.

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

C. Sotiriou, S. Loi, M. Piccart, 2019, Clinical Cancer Research.

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.

J. Baselga, B. Naume, C. Criscitiello, 2018, European journal of cancer.

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

R. Gelber, J. Baselga, Z. Aziz, 2021, European journal of cancer.

Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.

S. Loi, M. Piccart, C. Denkert, 2019, Journal of Clinical Oncology.

Prevention of Tumor Growth Driven by PIK3CA and HPV Oncogenes by Targeting mTOR Signaling with Metformin in Oral Squamous Carcinomas Expressing OCT3

V. Steele, A. Bode, I. Stijleman, 2015, Cancer Prevention Research.

C. Sotiriou, S. Loi, C. Denkert, 2015, JAMA oncology.

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial

A. Tutt, C. Geyer, Seigo Nakamura, 2023, Breast Cancer.